RA0802

antibody from Oursmab

Targeting: TACSTD2 EGP-1, GA733-1, M1S1, TROP2

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0802

Provider

Oursmab

Product name

Datopotamab (Biosimilar Reference Antibody) (TROP2)

Antibody type

Monoclonal

Description

Datopotamab deruxtecan (also known as Dato-DXd or DS-1062) is an investigational antibody-drug conjugate (ADC) developed for the treatment of advanced solid tumors, most notably non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). It is composed of a humanized monoclonal antibody directed against TROP2, a linker, and a potent topoisomerase I inhibitor payload. Clinical trials have demonstrated promising efficacy in patients with heavily pretreated disease, leading to its Breakthrough Therapy Designation in the U.S. for certain NSCLC and breast cancer indications.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.